Experimental Lilly combination drug tops Zepbound in weight-loss trial
- Posted on September 30, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
Experimental Lilly combination drug tops Zepbound in weight-loss trial
By Patrick Wingrove Sept 30 (Reuters) - Eli Lilly said on Wednesday its experimental combination weight-loss drug outperformed its blockbuster Zepbound in a head-to-head trial, intensifying the competition with Danish rival Novo Nordisk for new, more effective obesity therapies. The Indianapolis-based drugmaker said patients with diabetes on the highest tested dose of EloraTZP, which combines
